Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03579901
Other study ID # CLIN-17-008
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date April 6, 2018
Est. completion date February 28, 2033

Study information

Verified date March 2023
Source Motiva USA LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the safety and effectiveness Motiva Implants® in women who are undergoing primary breast augmentation, primary breast reconstruction or revision breast surgery.


Description:

Prospective, Single Arm, Multicenter Study. Following FDA approval, follow-up data will continue to be collected for all cohorts on adverse events, reoperations, patient satisfaction, physician satisfaction and quality of life for a total of 10 years.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 800
Est. completion date February 28, 2033
Est. primary completion date August 30, 2032
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria - Genetic female. - Patient is seeking one of the following procedures: Primary Breast Augmentation Primary Breast Reconstruction Revision Augmentation Revision Reconstruction - Patient has adequate tissue available to cover implant(s). - Willingness to follow all study requirements including agreeing to attend all required follow-up visits and signs the informed consent. - Agrees to have device returned to Establishment Labs if explanted. - Willing to undergo Magnetic Resonance Imaging (MRI) evaluation of medically advised. Exclusion Criteria: - Has any breast disease considered to be pre-malignant in one or both breasts or is reporting mutations in BRCA1 or BRCA2 without a previous bilateral mastectomy or an untreated cancer of any type. - Has inadequate or unsuitable tissue (e.g., due to radiation damage, ulceration compromised vascularity, history of compromised wound healing). - Has an abscess or infection. - Is pregnant or nursing or has had a full-term pregnancy or lactated within 6 months of enrollment. - Is taking any drugs that would interfere with blood clotting, or that might result in elevated risk and or significant postoperative complications. - Has any medical condition such as obesity (BMI = 40), diabetes, autoimmune disease, chronic lung or severe cardiovascular disease that might result in unduly high surgical risk and or significant postoperative complications. - Has any connective tissue/autoimmune disorder or rheumatoid disease, such as systemic lupus erythematosus, discoid lupus, scleroderma, or rheumatoid arthritis, among others. - Has any condition that impedes the use of magnetic resonance imaging (MRI) including implanted metal device, claustrophobia or other conditions that would make MRI scan prohibited. - Has a history of psychological characteristics that are unrealistic or unreasonable given the risks involved with the surgical procedure. - Has been implanted with any non-FDA approved breast implant. - Has been implanted with any silicone implant other than breast implants. - HIV positive (based on medical history). - Has been diagnosed with anaplastic large cell lymphoma (ALCL). - Works for Establishment Labs, Motiva USA or any of their subsidiaries, the study surgeon, or ICON the Contract Research Organization (CRO) that is helping to conduct the study or are directly-related to anyone that works for Establishment Labs, Motiva USA or any of their subsidiaries, the study surgeon, or the CRO.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Silicone gel-filled breast implants - Motiva Implants® Investigational breast implants
Breast augmentation

Locations

Country Name City State
Germany Plastische Chirurgie im Medienhafen Dusseldorf
Sweden Akademikliniken HJ AB Stockholm
Sweden Victoriakliniken Stockholm
United States Emory University Hospital Atlanta Georgia
United States Brian M. Kinney, MD, FACS-Excellence in Plastic Surgery Beverly Hills California
United States Gerald Minitti, MD, FACS Beverly Hills California
United States Northwestern Plastic Surgery Chicago Illinois
United States Northwestern Specialists in Plastic Surgery, S.C. Chicago Illinois
United States Cleveland Clinic Main Campus Cleveland Ohio
United States Movassaghi Plastic Surgery & Ziba Medical Spa Eugene Oregon
United States Strock Plastic Surgery Fort Worth Texas
United States The Center for Cosmetic Surgery Golden Colorado
United States Partners in Plastic Surgery of West Michigan Grand Rapids Michigan
United States Mark D. Epstein, MD, FACS/ Center for Aesthetic Surgery Hauppauge New York
United States Houston Methodist Houston Texas
United States MD Anderson Cancer Center Houston Texas
United States Meridian Plastic Surgery Center Indianapolis Indiana
United States CaloAesthetics® Plastic Surgery Center Louisville Kentucky
United States Maxwell Aesthetics, PLLC Nashville Tennessee
United States Fifth Avenue Millennium Aesthetic Surgery, PLLC New York New York
United States May Center for Mount Sinai Doctors New York New York
United States NYU Plastic Surgery Associates New York New York
United States Portland Plastic Surgery Portland Oregon
United States Body by Z Providence Rhode Island
United States Parkcrest Plastic Surgery Saint Louis Missouri
United States Steven Teitelbaum, MD, FACS Santa Monica California
United States Glicksman Plastic Surgery Sea Girt New Jersey
United States The Wall Center for Plastic Surgery Shreveport Louisiana
United States Rafael Gottenger, MD Plastic Surgery South Miami Florida
United States William P. Adams Plastic Surgery University Park Texas
United States PeaceHealth Plastic Surgery Vancouver Washington
United States Westlake Cosmetic Surgery Center Westlake Village California

Sponsors (1)

Lead Sponsor Collaborator
Motiva USA LLC

Countries where clinical trial is conducted

United States,  Germany,  Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Analyze and report the total adverse events rate ("any complication)" of the Silicone Gel filled Motiva Implants®. Kaplan-Meier analysis of adverse events will be conducted by time period for each type of adverse event. 10 Years
Primary Analyze patient satisfaction on a 5-point Likert scale post-implant for all implantation groups. 10 Years
Secondary Kaplan-Meier analysis of all complications, including reoperation and explantation 10 Years
Secondary Cox regression analyses for the following endpoints: Capsular contracture III/IV, Breast Pain, Infection, and Implant Rupture 10 Years
Secondary Kaplan-Meier analysis of rupture. 10 Years
Secondary Kaplan-Meier analysis of connective tissue disease (CTD) and CTD signs/symptoms 10 Years
Secondary Kaplan-Meier analysis of Cancer (Breast Cancer, Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL), and others) 10 Years
Secondary Patient Satisfaction with Breast (BREAST-Q™) Questionnaire 10 Years
Secondary Physician Satisfaction (5-point Likert scale) 10 Years
Secondary Validated Quality of Life questionnaires 10 Years
Secondary Breast Measurements (Net Chest Circumference and Hemi-Circumference) change from baseline 10 Years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06013514 - Post-market Prospective Clinical Study of Nagor Perle Mammary Implants
Recruiting NCT02777476 - Clinical Performance of B-Lite® Light Weight Breast Implant N/A
Withdrawn NCT01857765 - Breast Augmentation Rehabilitation Program N/A
Recruiting NCT06147661 - Primary Aesthetic Breast Augmentation: Comparative Study Between Breast Implants and Autograft of Adipose Tissue
Completed NCT00858052 - Core Study of the Safety and Effectiveness of IDEAL IMPLANT(R) Saline-filled Breast Implants N/A
Completed NCT01874652 - Assessment of Safety & Efficacy of Light Weight Breast Implant Phase 2